Meeting
2019 ASCO Annual Meeting
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
Authors
Amir A. Jazaeri
The University of Texas - MD Anderson Cancer Center, Houston, TX
Amir A. Jazaeri , Emese Zsiros , Rodabe Navroze Amaria , Andrew S. Artz , Robert P. Edwards , Robert Michael Wenham , Brian M. Slomovitz , Axel Walther , Sajeve Samuel Thomas , Jason Alan Chesney , Robert Morris , KOJI MATSUO , Stephanie Gaillard , Peter Graham Rose , Jesus Garcia Donas , Jacqueline Maria Tromp , Fatemeh Tavakkoli , Huiling Li , Maria Fardis , Bradley J. Monk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03108495
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2538)
DOI
10.1200/JCO.2019.37.15_suppl.2538
Abstract #
2538
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
First Author: Amod Sarnaik
Poster
2018 ASCO Annual Meeting
A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.
First Author: Amir A. Jazaeri
Poster
2019 ASCO Annual Meeting
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
First Author: Amod Sarnaik